Human KRAS Knockout Cell Line-Hela

Name: Human KRAS Knockout Cell Line-HeLa
SKU: CSC-RT0518

Cat.No. : CSC-RT0518

Host Cell: Hela Target Gene: KRAS

Size: >1x10^6 cells/vial, 1 mL Validation: Sequencing

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Documents

Cat. No.	CSC-RT0518
Description	This cell line is a stable cell line with a homozygous knockout of human KRAS using CRISPR/Cas9.
Target Gene	KRAS
Gene ID	3845
Genotype	KRAS (-/-)
Host Cell	Hela
Host Cell Species	Homo sapiens (Human)
Cell Type	Epithelial
Size	>1x10^6 cells/vial, 1 mL
SequencingResult	Homozygous: 1 bp insertion in exon

Revival	Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.
Media Type	Cells were cultured in DMEM supplemented with 10% fetal bovine serum.
Growth Properties	Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO₂. Split at 80-90% confluence, approximately 1:4-1:6.
Freeze Medium	Complete medium supplemented with 10% (v/v) DMSO

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Documents

Quick Inquiry

Background

Applications

Publications

Q & A

Customer Reviews

KRAS (Kirsten rat sarcoma viral oncogene homolog) is a gene that encodes a protein involved in cellular signaling. As part of the RAS oncogene family, the KRAS gene is related to the HRAS and NRAS genes and is an integral part of the MAPK/ERK signaling pathway, which mediates various cellular functions, including proliferation, survival, and growth.

Mutations in the KRAS gene are known to be associated with various types of cancer, making it one of the most studied genes in oncology. KRAS mutations are particularly common in pancreatic, colorectal, and lung cancers. In pancreatic ductal adenocarcinoma (PDAC), nearly 90% of cases exhibit KRAS mutations, making it a key target for therapeutic intervention. Similarly, approximately 40% of colorectal cancers and 15-25% of lung adenocarcinomas carry KRAS mutations. Despite the importance of KRAS, direct targeting of KRAS has been challenging due to the protein’s high affinity for GTP/GDP and lack of binding sites suitable for drug design.
Recent advances show promise, particularly the development of KRAS G12C inhibitors, which specifically target the mutant form of the protein found in certain cancers. Drugs such as sotorasib and adagrasib have shown efficacy in treating patients with KRAS G12C mutant non-small cell lung cancer, marking a major breakthrough in precision oncology.

Human KRAS knockout HeLa cell lines are valuable tools in biomedical research. Here are a few key applications of human KRAS knockout HeLa cell lines:

Cancer Research: The KRAS gene is frequently mutated in various cancers, making the KRAS knockout HeLa cell line valuable for studying oncogenic mechanisms. Researchers can study how loss of KRAS affects cell signaling, tumor growth, and metastasis, providing insights into potential therapeutic targets.

Drug Screening: These cell lines are an important tool for high-throughput screening of anticancer drugs. By evaluating the efficacy and toxicity of new compounds in KRAS knockout HeLa cells, scientists can identify drug candidates that selectively target KRAS mutant pathways.

Gene Function Studies: KRAS knockout HeLa cells enable researchers to study the role of KRAS in cellular processes such as cell proliferation, differentiation, and apoptosis.

Signal Transduction Studies: KRAS is a key player in the RAS/MAPK signaling pathway. Using knockout cell lines, researchers can dissect the complexity of the pathway and determine how KRAS interacts with other proteins and contributes to signaling, which is critical for developing pathway-specific inhibitors.

Study of Resistance Mechanisms: Cancer cells often become resistant to therapies. By using KRAS knockout HeLa cells, researchers can explore how the loss of KRAS affects resistance mechanisms.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

First Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

First Name

Country *

Email *

Human KRAS Knockout Cell Line-Hela

Cell Line Information

Cell Culture Information

Safety and Packaging

Documents

Background

Applications

Publications

Q & A

Customer Reviews

Related Services